 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction : |
(Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
| Data: | 2020 |
| Resum: | Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). We prospectively evaluated 40 patients with a first STEMI, LVEF < 50% and treated with primary percutaneous coronary intervention in which PCSK9 was measured 24 h postreperfusion. All patients underwent cardiac magnetic resonance imaging 1 week and 6 months after STEMI. Baseline characteristics were compared across median values of PCSK9. The association between PCSK9 levels and LVEF at 6 months was evaluated by analysis of covariance. The mean age of the sample was 60 ± 12 years and 33 (82. 5%) were male patients. The infarct location was anterior in 27 patients (67. 5%), and 9 patients (22. 5%) were Killip class ≥ II. The mean 1 week and 6 month LVEF were 41 ± 7% and 48 ± 10%, respectively. The mean PCSK9 was 1. 93 ± 0. 38 U/mL. Testing the association between serum PCSK9 and 6 month LVEF with analysis of covariance revealed an inverse relationship (r = −0. 35, P = 0. 028). After multivariate adjustment, circulating PCSK9 remained significant and inversely associated with 6 month LVEF (P = 0. 002). In patients with a first STEMI with reduced ejection fraction at index admission and treated with primary percutaneous coronary intervention, circulating PCSK9 was associated with lower LVEF at 6 months. |
| Ajuts: | Ministerio de Economía y Competitividad 16/11/00420 Ministerio de Economía y Competitividad 16/11/00486 Ministerio de Economía y Competitividad 16/11/00403 Ministerio de Economía y Competitividad PIE15/00013 Instituto de Salud Carlos III PI17/01836 |
| Nota: | Altres ajuts: Conselleria d'Educació, Investigació, Cultura i Esport GV/2018/116 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | PCSK9 ; Left ventricular ejection fraction ; Cardiac magnetic resonance ; ST-segment elevation myocardial infarction |
| Publicat a: | ESC Heart Failure, Vol. 7 (february 2020) , p. 117-122, ISSN 2055-5822 |
